0000000000667503

AUTHOR

Hervé Decousus

showing 2 related works from this author

Treatment of pulmonary embolism.

2015

International audience; The treatment of pulmonary embolism is going to be deeply modified by the development of Direct Oral Anticoagulants (DOACs). There are currently three anti-Xa factors (rivaroxaban, apixaban, edoxaban) and one anti-IIa factor (dabigatran) labeled by the FDA and the EMA. All these drugs are direct anticoagulant, orally effective, without the need for adaptation to hemostasis test. As kidney excretion is involved for all of them, they are contra-indicated in patients with severe renal failure (creatinine clearance<30mL/min according to Cockcroft & Gault formula). All the anti-Xa factor drugs are metabolized by liver cytochromes and then contra-indicated in case of liver…

medicine.drug_classPyridinesPyridones[SDV]Life Sciences [q-bio]PopulationRenal functionRisk AssessmentAntithrombinsDabigatranchemistry.chemical_compoundRivaroxaban[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemEdoxaban[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyMedicineHumanseducationeducation.field_of_studyRivaroxabanClinical Trials as Topic[ SDV ] Life Sciences [q-bio]business.industryMedicine (all)AnticoagulantGeneral MedicineVenous Thromboembolism[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicine.disease3. Good healthPulmonary embolismDabigatranThiazolesAntithrombins; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiazoles; Venous Thromboembolism; Medicine (all)chemistryAnesthesiaPyrazolesApixabanbusinessPulmonary Embolism[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologymedicine.drugFactor Xa Inhibitors
researchProduct

Low-molecular-weight heparin to prevent recurrent venous thromboembolism in pregnancy: Rationale and design of the Highlow study, a randomised trial …

2016

Summary Background Women with a history of venous thromboembolism (VTE) have a 2% to 10% absolute risk of VTE recurrence during subsequent pregnancies. Therefore, current guidelines recommend that all pregnant women with a history of VTE receive pharmacologic thromboprophylaxis. The optimal dose of low-molecular-weight heparin (LMWH) for thromboprophylaxis is unknown. In the Highlow study (NCT 01828697; www.highlowstudy.org ), we compare a fixed low dose of LMWH with an intermediate dose of LMWH for the prevention of pregnancy-associated recurrent VTE. We present the rationale and design features of this study. Methods The Highlow study is an investigator-initiated, multicentre, internation…

Adultmedicine.medical_specialtymedicine.drug_classPregnancy Complications CardiovascularLow molecular weight heparinHemorrhage030204 cardiovascular system & hematologylaw.inventionYoung Adult03 medical and health sciencesClinical trials0302 clinical medicineRandomized controlled trialRecurrencePregnancylawInternal medicineVenous thrombosisSecondary PreventionHumansMedicinecardiovascular diseasesPregnancy030219 obstetrics & reproductive medicineProphylaxisbusiness.industryPostpartum PeriodAbsolute risk reductionAnticoagulantsVenous ThromboembolismHematologyHeparinHeparin Low-Molecular-Weightmedicine.diseaseequipment and suppliesLMWHSurgeryClinical trialVenous thrombosisTreatment OutcomeGestationFemalebusinessmedicine.drug
researchProduct